We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$20B
Turnover
18.48%
1-Year Est. Return
154.41%
This Fund
S&P 500
This Quarter
Est. Return
+2.27%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.4B
AUM Growth
+$337M
(+2%)
Cap. Flow
+$511M
Cap. Flow
% of AUM
2.93%
Top 10 Holdings %
Top 10 Hldgs %
73.49%
Holding
93
New
8
Increased
18
Reduced
6
Closed
9
Avg Time Held
3.5
years
Top 10 Avg Time Held
4.6
years
Top 20 Avg Time Held
3.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$194M |
| 2 |
GRAIL Inc
GRAL
|
+$151M |
| 3 |
Insmed
INSM
|
+$127M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
+$42M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$31.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ultragenyx Pharmaceutical
RARE
|
+$63.8M |
| 2 |
Immunocore
IMCR
|
+$51.4M |
| 3 |
Terns Pharmaceuticals
TERN
|
+$38.4M |
| 4 |
BioNTech
BNTX
|
+$25.6M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.57% |
| 2 | Miscellaneous | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
LB Pharmaceuticals
LBRX
$1.18B
| $4.93M | 0.03% |
200,000
| – | – |
2025 Q3
2 quarters
|
|
77
Verastem
VSTM
$791M
| $3.1M | 0.02% |
+584,757
| New | +$3.61M |
2026 Q1
0 quarters
|
|
78
TScan Therapeutics
TCRX
$16.1M
| $2.81M | 0.02% |
2,784,792
| – | – |
2021 Q3
18 quarters
|
|
79
Skye Bioscience
SKYE
$6.95M
| $968K | 0.01% |
196,905
+15,575
| +9% | +$102K |
2024 Q2
7 quarters
|
|
80
Sana Biotechnology
SANA
$698M
| $894K | 0.01% |
310,483
| – | – |
2023 Q1
12 quarters
|
|
81
Aligos Therapeutics
ALGS
$31.5M
| $617K | ﹤0.01% |
83,055
| – | – |
2020 Q4
21 quarters
|
|
82
Tyra Biosciences
TYRA
$1.26B
| $406K | ﹤0.01% |
10,607
| – | – |
2023 Q4
9 quarters
|
|
83
DELISTED
Surrozen Inc Warrant
SRZNW
| $13.3K | ﹤0.01% |
833,333
| – | – |
2021 Q3
18 quarters
|
|
84
Acrivon Therapeutics
ACRV
$73.7M
| – | – |
-22,809
| Closed | -$55K | – |
|
|
85
BioCryst Pharmaceuticals
BCRX
$2B
| – | – |
-2,822,727
| Closed | -$22M | – |
|
86
4D Molecular Therapeutics
FDMT
$683M
| – | – |
-475,737
| Closed | -$3.57M | – |
|
87
KALA BIO
KALA
$3.62M
| – | – |
-36,081
| Closed | -$1M | – |
|
88
DELISTED
Nuvalent
NUVL
| – | – |
-143,937
| Closed | -$14.5M | – |
|
|
89
Ultragenyx Pharmaceutical
RARE
$1.45B
| – | – |
-2,772,692
| Closed | -$63.8M | – |
|
|
90
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-950,000
| Closed | -$38.4M | – |
|
91
Vir Biotechnology
VIR
$1.71B
| – | – |
-542,539
| Closed | -$3.27M | – |
|
92
DELISTED
Ventyx Biosciences
VTYX
| – | – |
-2,349,280
| Closed | -$21.2M | – |
|
Similar funds
SA
Baker Bros. Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Baker Bros. Advisors held 93 positions worth $17.4B, up 2% from $17.1B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Baker Bros. Advisors's Q1 2026 filing shows 8 new, 18 increased, 6 reduced and 9 closed positions. Its largest new stake was Mirum Pharmaceuticals: 445,975 shares worth $41.2M. The largest sale was Ultragenyx Pharmaceutical, an estimated $63.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.
- Baker Bros. Advisors's largest Q1 2026 buy was Mirum Pharmaceuticals: 445,975 shares worth $41.2M.
- Baker Bros. Advisors added most to Praxis Precision Medicines in Q1 2026, an estimated $194M increase.
- Baker Bros. Advisors's biggest Q1 2026 reduction was Immunocore, cutting an estimated $51.4M.
- Baker Bros. Advisors fully exited Ultragenyx Pharmaceutical in Q1 2026, selling an estimated $63.8M.
- Baker Bros. Advisors's ten largest holdings make up 73% of its $17.4B portfolio in Q1 2026.
- Baker Bros. Advisors opened 8 new positions and closed 9 in Q1 2026.
- Baker Bros. Advisors's portfolio value rose 2% quarter-over-quarter to $17.4B.
Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.